<DOC>
	<DOCNO>NCT00461981</DOCNO>
	<brief_summary>The primary objective study describe level serum antibody cellular immune response confer FluMist TIV influenza virus strain .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Immune Responses FluMist®</brief_title>
	<detailed_description>The primary objective study describe level serum antibody cellular immune response confer FluMist TIV antigenically match antigenically mismatch influenza virus strain . The secondary objective study describe safety FluMist TIV subject 12 &lt; 36 month age .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age 12 &lt; 36 month ( reach 1st year yet reach 3rd year birthday ) time randomization Written inform consent HIPAA authorization obtain subject 's legal representative Ability subject 's legal representative understand comply requirement study Subject 's legal representative available telephone Ability complete followup period 180 day final study vaccination require protocol History hypersensitivity component FluMist TIV , include egg egg product History hypersensitivity gentamicin Any known immunosuppressive condition immune deficiency disease ( include HIV infection ) , ongoing receipt immunosuppressive therapy Household contact immunocompromised ( participant also avoid close contact immunocompromised individual least 21 day study vaccination ) History GuillainBarré syndrome Any prior history wheeze asthma Acute febrile ( ≥100.0°F oral equivalent ) and/or clinically significant respiratory illness ( e.g. , cough sore throat ) within 72 hour prior either study vaccination Use aspirin aspirincontaining product within 30 day prior randomization , expect receipt 180 day final study vaccination Receipt prior influenza vaccine Use antiinfluenza medication ( include amantadine , rimantadine , oseltamivir , zanamivir ) within 14 day prior randomization , expect receipt 35 day final study vaccination Administration live virus vaccine , measles , mumps , rubella , varicellacontaining vaccine ( ) , within 30 day prior randomization , expect receipt 30 day final study vaccination Administration inactivate ( i.e. , nonlive ) vaccine within 14 day prior randomization , expect receipt within 14 day 14 day either study vaccination Receipt investigational agent within 30 day prior randomization , expect receipt 180 day final study vaccination ( use license agent indication list package insert permit ) Receipt blood product within 90 day prior randomization , expect receipt 35 day final study vaccination Family member household contact employee research center otherwise involved conduct study Any condition opinion investigator would interfere evaluation vaccine interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Live , attenuate influenza virus vaccine ( LAIV )</keyword>
	<keyword>Trivalent inactivate influenza virus vaccine ( TIV )</keyword>
	<keyword>FluMist</keyword>
</DOC>